Intercept Pharma

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Intercept Pharma reports robust earnings, eyes growth amid competitive challenges

Intercept Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic advancements, and a focus on innovation and market expansion.
The company's achievements in sales growth, patent protection, and financial stability position it well for future growth and leadership in the PBC and NASH markets.
Challenges in competitive dynamics and regulatory landscape require proactive strategies, while opportunities in new programs and market developments offer avenues for continued success.
Overall, Intercept Pharma's performance underscores a resilient and forward-thinking approach to navigating the complexities of the pharmaceutical industry and driving sustainable growth.

Intercept Pharma reports growth in sales and navigates NASH landscape

Intercept Pharma's Q1 2023 performance saw growth in net sales and strong sales performance of OCALIVA.
The company's focus on F3-like NASH patients and competitive positioning of OCA are key strengths.
Challenges include pricing strategy discussions and questions on combination approaches.
Opportunities lie in addressing AdCom discussions, expanding prescriber base, and preventing cirrhosis progression.

Intercept Pharma reports strong Q2 earnings, eyes FDA relations

Intercept Pharma's strong performance in Q2 2023 shows progress towards profitability by 2024. The company is addressing challenges in FDA relations and study enrollments while leveraging market opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences

What does the future hold for these two biotech stocks?

Better Buy: Intercept Pharmaceuticals  vs.  Gilead Sciences

NEW YORK, Jan.  29, 2020  (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has completed patient enrollment in its Phase 3 REVERSE study evaluating obeticholic acid (OCA) for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).

Intercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASH

Intercept's chances of remaining independent over the long-term are slim.

Where Will Intercept Pharmaceuticals Be in 5 Years?

Beyond Meat

Etsy

Immunomedics

Match Group

MACOM Technology Solutions Holdings

Unilever

As markets continue to hit all-time highs, consider taking profits in these stocks to sell before their companies report slowing growth.

The 7 Stocks That Cautious Investors Should Sell Now

Amarin Corporation Plc

Amarin and Intercept Pharmaceuticals could trounce the broader markets this year.

2 Mid-Cap Biotech Stocks to Buy Right Now

FDA Decision For Intercept's NASH Drug Ocaliva Delayed; Opportunity Presents Itself

Arrowhead Pharmaceuticals

Flushed with cash, bigger biotech stocks are on the hunt. These 3 smaller drug makers could be the next buyout targets in the new year.

3 Biotech Stocks to Bank on for Buyouts in 2020

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT), which is considered the frontrunner in the race for a non-alcoholic steatohepatitis, or NASH, drug, are fairly valued at current levels, according to an analyst at Citigroup.

Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced In

bluebird bio

Amicus Therapeutics

Global Blood Therapeutics

uniQure

5 Best Mid-Cap Biotech Acquisition Targets

The latest earnings report revealed rapid pipeline advancement and robust sales traction for the PBC franchise.

Intercept: History May Repeat Itself

Company submits Marketing Authorization Application to the European Medicines Agency for obeticholic acid in patients with fibrosis due to NASH

Intercept (ICPT) Provides Regulatory Update

Intercept Pharmaceuticals: Blockbuster Therapy Unveils An Upside Catalyst

Solid interim results from an ongoing study gave investors something to cheer about.

Here's Why Intercept Pharmaceuticals Stock Rose 48.9% in November

NEW YORK, Dec.  05, 2019  (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the positive results from the interim analysis of the Phase 3 REGENERATE study of obeticholic acid (OCA) in patients with fibrosis due to nonalcoholic steatohepatitis (NASH) have been published in   The Lancet  . This is the first peer-reviewed publication of positive results from a pivotal study evaluating an investigational therapy for NASH.

Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Intercept (ICPT) Up 48.6% Since Last Earnings Report: Can It Continue?

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space

NEW YORK, Dec.  02, 2019  (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jason Campagna, M.D., PhD., as Chief Medical Officer. He will join Intercept’s executive leadership team and report directly to Mark Pruzanski, M.D., President and Chief Executive Officer. In his new role, Dr. Campagna will provide strategic medical and scientific oversight for Intercept, and work in close collaboration with the company’s Research & Development, Regulatory, Medical Affairs and Safety & Pharmacovigilance departments.

Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer

Allergan

CymaBay Therapeutics

Conatus Pharma

Galmed Pharmaceuticals

Madrigal Pharmaceuticals

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

NASH Scorecard Year to Date: The Winners and the Losers

Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.

Intercept's (ICPT) NDA for NASH Drug Gets Priority Review

Intercept Pharmaceuticals stock rocketed Monday after FDA regulators granted its NASH treatment priority review and after competing biotech company CymaBay scrapped its rival drug.
The post This Biotech Flew To A 7-Month High On A Double Serving Of Good News appeared first on Investor's Business Daily.

This Biotech Flew To A 7-Month High On A Double Serving Of Good News

First Majestic Silver

Aimmune Therapeutics

Antero Midstream Partners

Exelixis

Innovative Industrial Properties

Lovesac Company

Livongo Health Inc

Meet Group

Ping Identity Holding Corp

Pinterest

Redfin

Stitch Fix

StoneCo

Teva Pharmaceutical

Trupanion

Big gains could be just a click of the buy button away.

20 Stocks That Could Double Your Money in 2020

Genfit - ADR

Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?

Better Buy: Intercept Pharmaceuticals or Genfit?

Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.

Intercept (ICPT) Earnings and Sales Miss Estimates in Q3

Intercept Pharmaceuticals, Inc. (ICPT) CEO Mark Pruzanski on Q3 2019 Results - Earnings Call Transcript

Intercept (ICPT) delivered earnings and revenue surprises of -10.21% and -2.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Lags Revenue Estimates

News for Intercept Pharma Stock (ICPT)